Archived posting to the Leica Users Group, 2003/12/05
[Author Prev] [Author Next] [Thread Prev] [Thread Next] [Author Index] [Topic Index] [Home] [Search]
- --D28099_37E04C.AA
Content-Type: text/plain;
Content-Transfer-Encoding: quoted-printable
AFTER-HOURS TRADING - BREAKING NEWS
Get Quote - http://quote.money.cnn.com/quote/quote?symbols=3Dhtds
Hard to Treat Diseases Incorporated - HTDS - Announces: Receipt of Tuberci=
n Toxicity Study and Formation of Scientific Advisory Panel - Wednesday De=
cember 3, 8:04 pm ET
DELRAY BEACH, Fla.--(BUSINESS WIRE)--Dec. 3, 2003--Hard to Treat Diseases =
Incorporated (Pink Sheets: HTDS) announces today that the spokesperson for=
the independent medical group conducting the testing for HTTD (HTDS) has =
forwarded the formal Testing Results of Tubercin=AE's Toxicity Trials to H=
TTD.
Tubercin of five different concentrations was administered to five groups =
of mice. A pathologist at the University of Oklahoma Health Science Center=
performed autopsies. The mice were randomized and only the control mouse =
was known to the pathologist, as stated in the cover letter of the Patholo=
gy Report.
The report concludes, "All tissues evaluated, visceral organs and the brai=
n were essentially normal in appearance." "The importance of this report i=
s even better than I expected," stated the spokesperson for the medical gr=
oup. "As the testing continues and if the results are similar to those of =
Chemotherapy and or radiation with no harmful side effects, Tubercin has e=
normous potential for the treatment of cancer and the immune system."
The President and CEO of HTTD, Mr. Colm J. King is in the process of formi=
ng a Scientific Advisory Panel with leading Oncologists and Immunologists =
from prestigious institutions in the U.S. The panel will review the report=
s and results of Tubercin=AE's findings and will report back to Mr. King w=
ith the ongoing reports in layman language for the shareholders.
"We are continuing to receive promising results regarding Tubercin=AE and =
we're looking forward to additional positive results in the near future," =
stated Mr. King. "These tests prove that Tubercin=AE is non-toxic and is t=
he first step on the way to human clinical trials as well as the first pos=
itive breakthrough conducted in the United States with an independent medi=
cal group for Tubercin=AE.
Operating out of Delray Beach, Florida, Hard to Treat Diseases Incorporate=
d ("HTTD") holds the international marketing rights, except South Korea, t=
o Tubercin=AE, a patented immunostimulant developed for combating Cancer u=
nder medical patent (US Patent 6,274,356). The unique properties unlike ot=
her cancer products are clearly stated in the abstract summary of the pate=
nt... "A carbohydrate complex, which is a mixture of low molecular-weight =
polysaccharides of an arabinomannan structure extracted from Mycobacterium=
tuberculosis, is highly effective in treating various cancer patients wit=
hout incurring any adverse side effects."
Statements in this press release that are not historical facts are forward=
- -looking statements within the meaning of the Securities Act of 1933, as a=
mended. Those statements include statements regarding the intent, belief o=
r current expectations of the Company and its management. Such statements =
reflect management's current views, are based on certain assumptions and i=
nvolve risks and uncertainties. Actual results, events, or performance may=
differ materially from the above forward-looking statements due to a numb=
er of important factors, and will be dependent upon a variety of factors, =
including, but not limited to, our ability to obtain additional financing =
and access funds from our existing financing arrangements that will allow =
us to continue our current and future operations and whether demand for ou=
r product and testing service in domestic and international markets will c=
ontinue to expand. The Company undertakes no obligation to publicly update=
these forward-looking statements to reflect events or circumstances that =
occur after the date hereof or to reflect any change in the Company's expe=
ctations with regard to these forward-looking statements or the occurrence=
of unanticipated events.
i ylty nhmunk
vuskrz
syd c kjlyfiyx
- --D28099_37E04C.AA--